Avid Bioservices Inc (CDMO)

[eb0783]

Again I will post this which says there is NO subset referenced. I’m wondering why so many are trying to push this subset thing and this "piece of a small market." Could it be that someone wants us to think our PEARL is not worth much??

They are not working with a sliver or a part and, in fact, not even working with a data set where one has and another has not “A” biomarker. They are in fact identifying a biomarker profile which shows the patients getting the benefit from Bavi. In order to do that, the whole dataset is used, not a subset. [If you want to call the patients who did not get Bavi a sub-population and those that did get Bavi (random and blinded) another sub-population you can do that but that is already two different groups by definition and by protocol.] Everyone in the study already has exposed PS and naturally has the other proteins and cytokines. The biomarker profile will show which ones are increasing and which are decreasing and by how much.
________________________________________

The primary goal of the biomarker analysis is to identify a biomarker profile for patients that receive the most benefit from a bavituximab-containing therapeutic regimen. As specified in the study protocol, thousands of patient samples were collected to potentially identify biomarkers associated with improved outcome for patients receiving bavituximab. Peregrine is in the process of filing a new patent application directed to the use of the initial biomarker discovery which will be presented at the ESMO 2016 Congress. Additional patient sample testing and analysis is ongoing and may result in other biomarkers of importance.

In case you didn't catch it before these same biomarkers may turn out be used for Bavi in other, if not all cancers (imo). So if only a parsed piece of only 2nd Line NSCLC is used for calculations, that is very shorted sighted.

Our PEARL is worth much more than you are implying.

So why do you guys keep referencing subsets??

I am guessing the biomarker identifies a subset of the entire trial population that benefited from Bavi. Hopefully, it is a large enough % to make a material difference. As someone earlier referenced, we are talking about an overall $1 billion market for Second Line NSLC . If you start parsing that into segments that are too small, commercial success is limited and likely not economically viable.